It covers the analytical methods and comparability frameworks used to confirm that a biologic's three-dimensional folded structure matches a reference, including circular dichroism, differential scanning calorimetry, NMR-based comparability, and statistical equivalence testing. In this landscape, most filings classify these methods alongside the specific biologic or formulation being tested rather than as standalone instrumentation claims. That is why A61K and C07K subclasses dominate the technology composition rather than G01N, the classification most associated with measurement methods.

The assignee ranking is concentrated at the top: the leading assignee holds 488 records, and the top 5 combined account for 51.3% of the 3,141 records in scope. Below the top 10, which hold 63.8% of records between them, the ranking extends to 100 companies with a long tail of much smaller filers. Checking the current ranking directly is more reliable than relying on a fixed list, since positions can shift as new families publish.

Filings peaked at 187 in 2018 and have since eased; over the most recent complete years, 2021 to 2024, filings fell 15% from 108 to 92. Because publication typically lags filing by around 18 months, the 2025 and 2026 counts in any dataset are still incomplete and should not be read as a further decline. The honest read is a field that has cooled from its 2018 high rather than one that is accelerating or collapsing.

The clearest gap is in analytical method claims themselves: G01N, the subclass tied to material analysis and testing, covers only 15.5% of the 3,141 records against 68.3% for A61K and 57.7% for C07K. That suggests claim space is comparatively open around specific comparability protocols, statistical equivalence frameworks, and formulation-interference correction methods, rather than around the biologics being tested. Any first claim there should be checked against the leading assignees' existing filings before drafting, since some of that space may already be occupied by broad formulation claims.

Biosimilar comparability appears as a search term across this landscape but is not broken out as its own IPC subclass, so its patent footprint is distributed across A61K, C07K and G01N filings rather than concentrated in one classification. The representative filing in this landscape, covering NMR methods for antibody higher order structure comparability, illustrates the pattern: claims are framed around comparing manufacturing variability rather than a single fixed test. That framing tends to broaden what the claims can be read to cover, which is worth checking carefully during any competitive review.